Global expert on the regulatory issues of commercialization of in vitro diagnostics to support the company’s go to market strategies for ProSpectral™, its 3-second saliva-based COVID+ diagnostic.

REDMOND, WA, January 16, 2023 — Pattern Computer®, Inc. (PCI) is pleased to announce that Jeffrey N. Gibbs, Esq. is joining its Advisory Board. Gibbs is a director in the law firm of Hyman, Phelps, & McNamara.

Before entering private practice, he was an Associate Chief Counsel for Enforcement at the Food and Drug Administration. He previously served as General Counsel and then as Chairman of Food and Drug Law Institute’s Board of Directors.

He assists in vitro diagnostic and medical device companies with a variety of regulatory issues, including product jurisdictional questions, FDA product approval, pre-submissions, regulatory strategy, clinical studies, promotional and marketing programs, and product appeals.

Jeff Gibbs received FDLI’s Distinguished Service and Leadership Award in 2013, LMG Life Sciences FDA Medical Device Attorney of the Year Award in 2013, and was inducted to LMG Life Sciences Hall of Fame in 2018. Jeff was co-editor and co-author of Thomson Reuters 2013, 2015, and 2018 editions of “European Lawyer Reference: Commercialisation of Health Care, Jurisdictional.” He is co-editor and co-author of FDLI’s 2021 publication, “Diagnostics at a Crossroads: Navigating IVD Regulation in a Changing Environment.” Gibbs previously served on the Human Subjects Review Board of George Mason University, and has taught medical device law at the University of Maryland and George Washington University. Gibbs has published more than 100 articles regarding FDA regulation of devices and diagnostics.

“We could not be more delighted to have Jeffrey Gibbs joining the Pattern Computer team. At a time when we are advancing our ProSpectral™ COVID+ testing device into the latter stages of FDA approval, his advice will be invaluable in assuring we are on track. We look forward to having our 12 other current bio pipelines also benefit from his experience and counsel.” said Mark R. Anderson, CEO of Pattern Computer.

“I am excited to join the Pattern Computer Advisory Board. The technology offers the potential to address a wide range of critical diagnostic challenges,” Jeff Gibbs added.

About Pattern Computer

Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.

CONTACT: Denyse Hudson – 360.298-0658 – denyse@patterncomputer.com

The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.

Copyright © 2023 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, and ProSpectral are trademarks of Pattern Computer Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.